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Abstract
Background: Proteoglycan (PG) in the extracellular matrix (ECM) of the central nervous system
(CNS) may act as a barrier for neurite elongation in a growth tract, and regulate other
characteristics collectively defined as structural neural plasticity. Proteolytic cleavage of PGs
appears to alter the environment to one favoring plasticity and growth. Brevican belongs to the
lectican family of aggregating, chondroitin sulfate (CS)-bearing PGs, and it modulates neurite
outgrowth and synaptogenesis. Several ADAMTSs (a d isintegrin and metalloproteinase with
thrombospondin motifs) are glutamyl-endopeptidases that proteolytically cleave brevican. The
purpose of this study was to localize regions of adult CNS that contain a proteolytic-derived
fragment of brevican which bears the ADAMTS-cleaved neoepitope sequence. These regions were
compared to areas of Wisteria floribunda agglutin (WFA) reactivity, a common reagent used to
detect "perineuronal nets" (PNNs) of intact matrix and a marker which is thought to label regions
of relative neural stability.
Results: WFA reactivity was found primarily as PNNs, whereas brevican and the ADAMTS-
cleaved fragment of brevican were more broadly distributed in neuropil, and in particular regions
localized to PNNs. One example is hippocampus where the ADAMTS-cleaved brevican fragment
is found surrounding pyramidal neurons, in neuropil of stratum oriens/radiatum and the lacunosum
moleculare. The fragment was less abundant in the molecular layer of the dentate gyrus. Mostly
PNNs of scattered interneurons along the pyramidal layer were identified by WFA. In lateral
thalamus, the reticular thalamic nucleus stained abundantly with WFA whereas ventral posterior
nuclei were markedly immunopositive for ADAMTS-cleaved brevican. Using Western blotting
techniques, no common species were reactive for brevican and WFA.
Conclusion: In general, a marked discordance was observed in the regional localization between
WFA and brevican or the ADAMTS-derived N-terminal fragment of brevican. Functionally, this
difference may correspond to regions with varied prevalence for neural stability/plasticity.
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Background
Extracellular matrix (ECM) in the central nervous system
(CNS) is deposited in the extracellular space of the
neuropil and around a subset of neurons in the form of
distinctive perineuronal nets (PNNs), coverings of matrix
that ensheath perikarya, proximal dendrites and axon ini-
tial segments. The components of this matrix are aggregat-
ing proteoglycans (PGs), termed lecticans, that interact
with tenascin and hyaluronan to form complexes which
maintain an anionic environment in the extracellular
milieu of the CNS [1,2] (Fig. 1D). The core proteins of lec-
ticans bear covalently-linked, highly negatively-charged,
linear chondroitin sulfate (CS) chains that consist of glu-
curonic acid/N-acetylgalactosamine repeats, sulfated to
varying extents at the 4 and 6 positions [3]. Methods
developed to detect the lecticans in fixed brain sections
have employed: 1) antibodies that recognize CS epitopes
of the lecticans, 2) antibodies that recognize initial disac-
charides of CS chains exposed on the core protein after
digestion with chondroitinase ABC (Chase), 3) labeled
lectins that recognize "selective" monosaccharide compo-
nents of CS, and 4) antibodies that recognize the core pro-
tein.
Wisteria floribunda agglutinin (WFA) is a lectin that binds
to terminal N-acetylgalactosamine residues [4] and deco-
rates various structures, including PNNs in the CNS,
where its reactivity has been well-documented [5-7]. Vari-
Brevican processing and fragments formed by ADAMTS cleavage Figure 1
Brevican processing and fragments formed by ADAMTS cleavage. Schematic representation of brevican, its endog-
enous proteolytic fragments and their interaction with other components of brain ECM: (A) Secreted brevican core protein 
which bears 1–3 chondroitin sulfate chains (MW > 145 kD). (B) Secreted brevican core protein without chondroitin sulfate 
chains (MW = 145 kD). When cleaved by extracellular glutamyl-endopeptidases, the ADAMTSs (arrows in A and B), an N-ter-
minal, 55 kD fragment is formed (C) that contains a unique C-terminal murine (Ms) epitope sequence "EAMESE", homologous 
to the rat (Rt) "EAVESE" which are selectively recognized by respective neoepitope antibodies, anti-EAMESE or anti-EAVESE 
(C). A larger C-terminal fragment is formed upon ADAMTS cleavage (D). The > 145 kD and 145 kD isoforms of brevican or 
other lecticans in matrix form an tertiary aggregate complex with hyaluronan and tenascin-R (E) and when cleaved by 
ADAMTSs, the proteolytic degradation of brevican "loosens" the ECM complex (F).BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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ous rostral-caudal layers of rat cerebral cortex, and partic-
ularly the retrosplenial cortex, thalamus, cerebellum and
brain stem are regions that contain numerous PNNs
prominently labeled by WFA [6]. In rat neocortex, several
types of functional morphology are associated with WFA-
reactive PNNs [5,8]. Some data indicate that lectin bind-
ing identifies terminal N-acetylgalactosamine present on
neuronal cell surface glycoproteins [9], whereas others
suggest the reactivity seen with WFA may detect CS
directly. Importantly, WFA binding in nervous tissue co-
localizes with signal from antibodies raised against CSs
[10], and signal is lost when tissue sections are pre-treated
with Chase [11], suggesting that WFA binds indirectly or
directly to CS. Thus, WFA reactivity has become a standard
method of identifying CS-containing subsets of neurons
in the CNS that are surrounded by PNNs.
The lecticans, including brevican, aggrecan and the V2 iso-
form of versican, are highly expressed in the adult brain.
The deposition of these lecticans is heterogeneous in the
complex ECM of PNNs and in the neuropil [3] (Fig. 1E).
Functionally, CS side chains of the lecticans inhibit neur-
ite elongation and even may stabilize synapses in neural
networks [3,12,13]. Among the lecticans, brevican is
highly abundant in brain, where various isoforms are
found including a > 145 kD molecule that carries 1–3 CS
chains (Fig. 1A), a core 145 kD protein without CS (Fig.
1B), a 120 kD glycosylphosphatidylinositol-linked mem-
brane-bound form, and 55 kD N-terminal, and 80 kD C-
terminal fragments (Fig. 1C, 1D) that are the result of
endopeptidase cleavage of the holoprotein. The proteases
mainly responsible for cleavage of brevican are glutamyl-
endopeptidases, the ADAMTSs (adisintegrin and metallo-
proteinase with thrombospondin motifs) (Fig. 1E, 1F).
Several of these multi-domain proteases [14] are
expressed in brain (ADAMTS1, 4, 5, and 9) [15-17] (our
unpublished observations) and cleave aggrecan [18], ver-
sican [19] and brevican [20] (for review, see [21]).
ADAMTS-cleaved fragments of each lectican are found in
untreated nervous tissue extracts [16,19,20,22-24], indi-
cating that ADAMTSs are active proteases capable of cleav-
ing lecticans in a "normal" nervous system. Fragments of
lecticans may be localized in brain tissue sections by using
antibodies raised against the terminal, neoepitope
sequence of the core protein that is exposed after ADAMTS
cleavage [20,21,25,26]. Using an antibody that recognizes
the C-terminal residues (EAVESE) that are uncovered after
ADAMTS-induced release of the N-terminal fragment of
brevican [20], we noted that the distribution of this
immunoreactivity in rat hippocampus was markedly dif-
ferent from WFA reactivity in the same region. We
expected that the distribution of the signal from both rea-
gents would be similar, since both N- and C-terminal frag-
ments of brevican appear to be stable after cleavage [3],
and the preponderance of the C-terminal fragments bear
CS chains. Thus, the purpose of this study was to describe
the distribution and characteristic immunoreactivity for
the ADAMTS-cleaved fragment of brevican, and compare
this with WFA binding in the rodent CNS. The results
show a marked discordance between the two, with the
breadth of distribution of the ADAMTS-derived brevican
fragment being much wider than that of WFA reactivity.
Results
Brevican exists in rodent brain ECM as a holoprotein, in
part, with a central region that bears CS chains and glob-
ular terminal domains which do not. When brevican is
detected on Western blot using an N-terminal region anti-
body, a 55 kD, N-terminal fragment of brevican is promi-
nent. The predominant protease responsible for this
cleavage is ADAMTS-derived, glutamyl-endopeptidase
activity. The neoepitope antibody(s) used in these experi-
ments, anti-EAV(M)ESE, represents the C-terminal
sequence exposed on the N-terminal, 55 kD fragment of
brevican after ADAMTS cleavage [20] (Fig. 1). To verify
that this antibody recognizes ADAMTS-cleaved brevican,
the CS-bearing form of brevican was partially purified on
a DEAE anion exchange matrix, and the PG-containing
eluant was incubated with active human recombinant
ADAMTS4. As shown in Fig. 2, when a Western blot of the
DEAE extract was probed using an N-terminal region
monoclonal, anti-brevican antibody, a smear > 145 kD
was observed (Fig. 2A). After digestion by ADAMTS4, the
abundance of the holoprotein was markedly reduced with
the appearance of a 55 kD N-terminal fragment (Fig. 2C).
When probed with polyclonal anti-EAVESE, little or no
anti-EAVESE immunoreactive fragment was present in the
DEAE extract prior to digestion (since the fragment does
not bind the column) (Fig. 2B), however, after cleavage of
brevican by human recombinant ADAMTS4, the same 55
kD fragment was apparent (Fig. 2D). This indicates that
N-terminal, ADAMTS-cleaved brevican is recognized by
anti-EAVESE as a 55 kD, N-terminal fragment, the same
fragment detected using a general N-terminal region anti-
brevican antibody.
In an effort to identify the molecular species in rodent
brain detected by the N-terminal region, anti-brevican
antibody, those detected by anti-EAV(M)ESE, and by
biotin-WFA, cortical homogenates from rat and mouse
brain that were either pre-treated with Chase or were left
untreated were subjected to SDS-PAGE and probed with
the reagents (Fig. 3). When soluble brain extracts were
probed with the N-terminal region anti-brevican anti-
body, the pattern of brevican immunoreactivity included
a smear of immunoreactivity found at > 145 kD, a distinct
145 kD band and a 55 kD, N-terminal fragment of brevi-
can (Fig. 3A). Chase treatment eliminated the smear in the
mouse sample with an associated increase in the 145 kD
holoprotein without CS in both the mouse and rat sam-BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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ples (Fig 3A). Chase treatment did not alter the intensity
of the 55 kD fragment, and this same N-terminal fragment
was identified (alone) when the membrane was probed
with anti-EAVESE (rat) or anti-EAMESE (mouse) (Fig. 3B).
Interestingly, signals observed with streptavidin-HRP to
identify proteins on blots that bind to biotin-WFA did not
correspond to the molecular weight of any isoform of
brevican. In fact, the very high molecular weight smear
observed in cortical extract was the only WFA-reactive spe-
cies modestly diminished after incubation with Chase
(Ms, Fig. 3C). Two of the major bands seen in this blot,
however, were non-specific binding signals that were
present when membrane was probed with streptavidin-
HRP alone (Fig. 3C, right lane, Ms). When brain homoge-
nates were differentially centrifuged to obtain "mem-
brane" and "soluble" fractions, the majority of brevican
immunoreactivity was found in the soluble fraction (Fig.
3D, left panel, S), yet the generalized and ADAMTS
derived fragments were found in both fractions (Fig. 3D,
left and middle panel). However, the major signals
observed after probing with biotin-WFA were found
mainly in the "insoluble", membrane fraction (Fig. 3D,
right panel, I). These results indicate that brevican iso-
forms were undetected when probed with biotinylated
WFA on membranes. To verify that the effect of Chase on
the high molecular weight, WFA reactive smear was due
solely to degradation of polysaccharides (and not to pro-
teolytic activity potentially contained within the Chase
preparation), samples were treated with Chase in the
absence and presence of protease inhibitor cocktail (Fig.
3E, left panel). In both rat and mouse samples, the pattern
of WFA reactivity was identical, whether or not the sam-
ples contained protease inhibitor cocktail. These results
suggest that WFA does indeed bind to a high molecular
weight, CS moiety that is removed after Chase treatment,
but that is clearly different from brevican. To verify the
effectiveness of Chase digestion, the same membrane was
probed with anti-brevican antibody which showed com-
plete removal of CS chains and a marked increase in the
abundance of the core protein in Chase-treated samples
(Fig. 3E, right panel, rat only, mouse not shown) with no
change in the abundance of fragment.
This discordance between biotin-WFA and anti-brevican
reactivity was not region specific, because when cerebel-
lum, brain stem, temporal lobe and diencephalon extracts
were probed with anti-brevican, anti-EAMESE and biotin-
WFA, similar results were observed (Fig. 4). Nonetheless,
biotin-WFA was highly effective at identifying neurons in
the CNS that were surrounded by PNNs, and minor reac-
tivity was also found in the neuropil in both rat and
mouse tissue sections (Fig. 5A, 5B). Note the abundant
PNNs in retrosplenial cortex (arrows) and scattered PNNs
in parietal cortex. The intense signal was nearly abolished
by pre-incubating the tissue section with high concentra-
tions of Chase (Fig. 5C, 5D). When streptavidin-Alexa 594
was incubated alone, the section was completely blank
(not shown). In addition, immunoreactivity for anti-
EAV(M)ESE was not influenced at all by Chase pre-treat-
ment of a tissue section (not shown). These results suggest
that whatever moiety is bound by WFA is released upon
treatment with Chase, yet the N-terminal brevican frag-
ment that does not bear CS chains is unaffected by Chase
as would be predicted.
There are several regions of the brain where there is dis-
tinctive and discordant reactivity between WFA and the
ADAMTS-derived N-terminal fragment of brevican. Partic-
ularly, the reticular thalamic nucleus shows prominent
staining with WFA in both the rat and mouse (Fig. 6A, 6C,
and 6D, 6F) whereas the barrels of the ventral posteri-
olateral and posteriomedial thalamic nuclei are most evi-
dent in the rat, compared to the mouse (Fig. 6A and 6C
N-terminal and neoepitope fragment formed by ADAMTS  cleavage of brevican Figure 2
N-terminal and neoepitope fragment formed by 
ADAMTS cleavage of brevican. Recombinant ADAMTS4 
cleavage product of rat brevican is recognized by anti-
EAVESE: (A) Proteoglycan-containing fraction eluates of rat 
brain extracts from a DEAE cation exchange matrix were 
probed with anti-brevican. (B) Proteoglycan fraction was 
probed with anti-EAVESE, antibody raised against the C-ter-
minal neoepitope sequence of the ADAMTS-cleaved N-ter-
minal fragment of brevican. (C) Proteoglycan fraction after 
incubation with recombinant ADAMTS4 and probed with 
anti-brevican or (D) anti-EAVESE. After incubation with 
human recombinant ADAMTS4, brevican was proteolytically 
cleaved resulting in diminished full length brevican and the 
appearance of a 55 kD N-terminal fragment recognized by 
both anti-brevican and anti-EAVESE.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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Comparison of brevican, the ADAMTS-derived neoepitope of brevican and WFA reactivity in rat and mouse brain extracts Figure 3
Comparison of brevican, the ADAMTS-derived neoepitope of brevican and WFA reactivity in rat and mouse 
brain extracts. Western blot of brevican, EAV(M)ESE, and Wisteria floribunda agglutinin (WFA) in rodent brain extracts 
before and after chondroitinase digestion: Rat (Rt) and mouse (Ms) extracts were probed for (A) anti-brevican, (B) anti-
EAVESE (Rt) or anti-EAMESE (Ms), or (C) biotinylated WFA: Samples were treated with (+) and without (-) Chondroitinase 
ABC (Chase). (A+) The 145 kD core protein of brevican increased after Chase treatment, (B+) the proteolytic brevican frag-
ment remained unchanged, and (C+) only a high molecular weight WFA-reactive band was diminished in Ms. (C) After probing 
with WFA, multiple, unidentified lower molecular weight bands were observed along with less abundant, high molecular weight 
moieties. The right panel in (C) was probed with secondary, HRP-conjugated streptavidin alone, which revealed two, major 
non-specific bands. (D) After differential centrifugation of rat brain tissue, brevican immunoreactivity (left panel) was predomi-
nately found in the soluble fraction (S), whereas most of the WFA reactivity (right panel) was observed in the membrane 
"insoluble" fraction (I) whereas anti-EAVESE immunoreactivity (middle panel) was evident in both fractions. (E) Rt and Ms sam-
ples were treated with Chase in the absence (-) and presence (+) of a protease inhibitor cocktail (left panel) and probed with 
biotinylated-WFA. The high molecular weight smear is eliminated after treatment with Chase, but the protease inhibitor did 
not change the pattern. (right panel) The same membrane was probed with anti-brevican where complete removal of CS 
chains led to an increase in abundance of the core protein with no change in the abundance of fragment. Protease inhibitor had 
no effect on Chase action.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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with 6D and 6F). In contrast, anti-EAV(M)ESE immunore-
activity is weak in the reticular thalamus, but highly prom-
inent between the barrels in the posteriolateral and
medial nuclei (Fig. 6B, 6C, 6E and 6F). There were also
striking differences seen in the hippocampus and sur-
rounding cortex as well. Mostly the neuropil layers of the
dorsal hippocampus contain weak to absent staining with
WFA, the exceptions being the CA2-CA3 transition region,
the molecular layer of the lateral blade and the polymor-
phic layer (especially in the mouse) of the dentate gyrus
and the fasciola cinereum (Fig. 6G). However, clear PNNs
were found in and just adjacent to the pyramidal cell layer
in the stratum oriens in Ammon's horn. These hippocam-
pal neurons containing PNNs were more abundant in the
mouse compared to the rat (Fig. 6G, 6J). In addition, the
white matter regions of the corpus callosum, external cap-
sule and alveus were all intensely stained by WFA; how-
ever, at least a portion of this staining was not eliminated
after Chase treatment of the sections (not shown). Stain-
ing by anti-EAV(M)ESE showed comparatively intense
immunoreactivity in the hippocampal neuropil, espe-
cially the stratum oriens, and this staining reached the
pyramidal cell layer (Fig. 6H, 6K) where there was a cob-
blestone appearance of this layer (not shown). Scattered
PNNs were noted in and around the pyramidal cell layer,
Chondroitinase treatment of brain sections prior to binding  by WFA Figure 5
Chondroitinase treatment of brain sections prior to 
binding by WFA. Binding of Wisteria floribunda agglutinin 
(WFA) lectin after treatment with Chase. Paraformaldehyde-
fixed coronal sections from (A and C) rat and (B and D) 
mouse brain were probed with biotinylated-WFA (A and B) 
before and (C and D) after Chase treatment. Arrow = retro-
splenial cortex; arrow head = parietal cortex. Note the near 
elimination of reactivity after Chase treatment. All images 
were captured at 25× magnification. Scale bar represents 100 
μm.
Regional distribution of brevican, EAMESE and WFA reactiv- ity in rat brain Figure 4
Regional distribution of brevican, EAMESE and WFA 
reactivity in rat brain. Western blot of brevican, EAMESE, 
and biotinylated-Wisteria floribunda agglutinin (WFA) in 
extracts from various regions of mouse brain before and 
after Chase digestion: Cerebellum (CB), hippocampus (HC), 
brain stem (BS), temporal lobe (TL) and diencephalon (DE)) 
extracts were probed for (A) anti-brevican, (B) anti-EAMESE 
and (C) biotinylated-WFA. Samples were pre-treated with 
(+) and without (-) Chase. (A+) The 145 kD core protein of 
mouse brevican increased after chondroitinase treatment, 
(B+) the proteolytic fragment remained unchanged, and (C+) 
high molecular weight, biotinylated WFA reactive smears 
were only slightly affected by Chase.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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similar to WFA staining, and some of these appeared to
co-localize with WFA reactivity in the mouse (Fig. 6J, 6K,
6L). In the cerebellum, the lobular molecular layer was
weakly stained by WFA, the granular layer contained heav-
ily labeled neuropil and PNNs and lobule white matter
(Fig. 6M, 6P). The white matter was perfectly negative for
reaction product to EAV(M)ESE, however, marked immu-
noreactivity was observed in the granular layer, especially
as PNNs surrounding the aligned Purkinje cells that make
up the molecular-granular layer interface (Fig. 6N, 6O,
6Q, 6R). Interestingly, these aligned Purkinje neurons
have previously been shown to be labeled with parvalbu-
min but not by WFA [27].
Neurons with PNNs that contain EAV(M)ESE fragment
are not quite as abundant as those identified by WFA, but
they appear to have a broad distribution. PNNs contain-
ing the brevican fragment were broadly distributed in cer-
ebral cortex in layers distinct from PNNs surrounded by
WFA reactivity, (Fig. 7A – 7C). In murine cerebral cortex,
anti-EAMESE immunoreactivity was found mostly in deep
cortical layer IV where sporadic neurons containing WFA-
reactive PNNs were located. For WFA reactivity, an
intensely-stained region was primary somatosensory cor-
tex (Fig. 7B – 7C). However, most neurons with WFA reac-
tive PNNs were found in layer III, and the superficial
region of layer IV was deficient in PNNs positive for WFA
or anti-EAMESE (Fig. 7F). Both reagents show a similar
distribution in the rat (data not shown). Another region
of cortex that is intensely labeled by both WFA and anti-
EAV(M)ESE was retrosplenial cortex (at low magnifica-
tion, see Fig. 6G – 6L). Anti-EAVESE immunoreactive
PNNs and intense fiber staining were found in the hori-
zontal limb of the diagonal band, the medial septum and
in piriform cortex (not shown).
Immunoreactivity for brevican holoprotein was distrib-
uted throughout the CNS neuropil and in PNNs as has
been identified by others [7]. Neurons with PNNs that
contain brevican immunoreactivity are clearly more abun-
dant than those identified by WFA. Brevican immunoreac-
tivity was broadly distributed in cerebral cortex in layers
distinct from PNNs surrounded by WFA reactivity, (Fig.
8A – 8C), although there was a higher percentage of brev-
ican immunoreactive cells that co-localize with WFA com-
pared to that of EAV(M)ESE immunoreactivity. In murine
cerebral cortex, anti-brevican immunoreactivity was
found in neuropil and PNNs of cortical layers II, III and
deep layer IV and V, whereas the most abundant distribu-
tion of neurons containing WFA-reactive PNNs were
found in layer III. Both reagents showed a similar distribu-
tion in the rat (data not shown). A higher magnification
of cortex reveals PNNs that are positive for brevican and
WFA reactivity (Fig. 8D – 8F). A confocal micrograph of
retrosplenial cortex stained with anti-brevican, biotin-
WFA and DAPI, demonstrated that there are clearly PNNs
that co-localize and are reactive for both reagents (Fig. 8G
– denoted by arrows). While many PNNs were immuno-
reactive for brevican, other PNNs were reactive toward
WFA alone, (Fig. 8G – denoted by asterisk). PNNs reactive
with WFA and not brevican, expressed other CS-contain-
Histochemical localization of WFA and ADAMTS-derived  brevican fragment in rat and mouse brain Figure 6
Histochemical localization of WFA and ADAMTS-
derived brevican fragment in rat and mouse brain. 
Localization of Wisteria floribunda agglutinin (WFA) and 
ADAMTS-derived fragment of brevican in rat and mouse 
brain including lateral thalamus (A-F), hippocampus (G-L) and 
cerebellum (M-R): Epifluorescent micrographs of bioti-
nylated-WFA reactivity (A, D, G, J, M, and P, red), anti-
EAVESE (rat) immunoreactivity (B, H, N, green), anti-
EAMESE (mouse) immunoreactivity (E, K, Q, green) and 
merged composites of WFA and anti-EAVESE (C, I O), and 
WFA and anti-EAMESE (F, L, R) in fixed brain sections. 
Images A-L were captured at 25× magnification and M-R 
were captured at 100× magnification. Scale bar represents 
100 μm.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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ing PGs or N-acetylgalactosamine containing molecules.
A complete localization of anti-brevican, anti-
EAV(M)ESE, and biotinylated WFA PNNs and their reac-
tivity in the neuropil of the CNS, with semi-quantitation
for both reagents may be found in additional files [Addi-
tional file 1] (rat) [Additional file 2] (mouse).
Discussion
Recent evidence indicates that ECM molecules are impor-
tant regulators of structural neural plasticity, and regional
expression in the CNS may be indicative of their role.
Localization of brevican by immunohistochemistry [7,28]
and in situ hybridization [29,30] within the CNS revealed
high expression in cerebellar and cerebral cortex, hippoc-
ampus and thalamic nuclei and brain stem. It is localized
perisynaptically, it inhibits neurite outgrowth [31] and it
is thought to stabilize neural networks in the adult [13].
In contrast, conditions that augment the proteolytic cleav-
age of brevican, especially ADAMTS-induced cleavage, are
associated with enhanced neural plasticity [16,24,32].
Here, an antibody which selectively recognizes the
neoepitope sequence of brevican that is uncovered upon
proteolysis by an ADAMTS was used to map the distribu-
tion of this fragment in untreated rodent CNS. This pat-
tern was compared to the distribution of PNNs and
neuropil stained by the classical reagent WFA. By both
Western blot and immunochemistry, the ADAMTS-
derived fragment of brevican appeared to be stable, abun-
dant and widely-distributed. There was a discordance
between the regional and local expression of classical
PNNs identified by WFA and regions where the proteo-
lytic fragment of brevican was most highly expressed. In
addition, there appeared to be an association between
regions with significant deposition of the brevican frag-
ment and areas known to be involved in neural plasiticity
(eg. hippocampus), supporting the involvement of
ADAMTSs in neural plasticity mechanisms [16,21,24].
WFA staining in these regions was notably low.
A significant proportion of total brevican immunoreactiv-
ity in brain extracts was found as a fragment formed by
proteolytic cleavage of the intact holoprotein. In fact, all
antibodies raised against the brevican holoprotein,
intended only to detect the holoprotein, inherently recog-
nize either the N- or C-terminal proteolytically-cleaved
fragment. Proteolysis of lecticans may be an important
mechanism by which the nervous system overcomes inhi-
bition exerted by PGs during periods of neural plasticity.
After systemic injection of the excitotoxin, kainic acid [16]
or after discrete, unilateral lesion of the entorhinal cortex
[24], there was an increase in the abundance of an
ADAMTS-derived brevican fragment in the dentate gyrus,
the target of projections from entorhinal cortex and a
region where sprouting occurs in response to the lesion.
Thus, proteolytic cleavage of PGs may be a key mecha-
Identification of PNNs with antibody against the ADAMTS- derived fragment of brevican Figure 7
Identification of PNNs with antibody against the 
ADAMTS-derived fragment of brevican. Mouse PNNs 
immunoreactive for the ADAMTS-derived fragment of brevi-
can distinguished with anti-EAMESE (green) (A) were broadly 
distributed in cerebral cortex, but were especially prominent 
deep in cortical layer IV, which differs from the distinct pat-
tern of WFA staining of PNNs (B). The most intense region 
of WFA reactivity appears in cortical layer III of primary som-
atosensory cortex (B-C). Scattered WFA positive PNNs are 
also found in layer V. Images A-C were captured at 100× 
magnification. Scale bar represents 100 μm.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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nism involved in sprouting and reorganization of the den-
tate gyrus, whereas intact PGs may promote neural
stabilization.
There is debate in the literature about which molecule(s)
in the CNS are labeled by WFA, and here we investigated
whether WFA binds to the CS-bearing lectican, brevican.
WFA is a lectin that binds to N-acetylgalactosamine-
linked α or β to the 3 or 6 position of galactose [33]. WFA
is often used as marker for PNNs that contain CS chains,
yet only indirect evidence suggests that WFA binds to CS
polymers. Our data show that WFA clearly did not recog-
nize CS-containing brevican on Western blot of soluble
brain extracts, although there was at least one high molec-
ular weight WFA reactive band that was diminished upon
treatment with Chase. No corresponding bands were
observed at the molecular weights representing any iso-
form of brevican. In addition, the preponderance of brev-
ican was found in the soluble fraction of brain extract,
whereas WFA reactivity was mainly located in the particu-
late, insoluble fraction after differential centrifugation of
brain extract. These results reveal that WFA binds mole-
cules that differ from the lectican, brevican, although the
possibility that WFA has a differential affinity for selected
sulfated forms of CS cannot be excluded. Murakami et al
has gathered convincing data that indicates that WFA
binds to cell surface glycoproteins. This group showed
that terminal N-acetylgalactosamine residues, which are
present on neuronal cell surface glycoproteins, are respon-
sible for the PNN reactivity seen with WFA lectin binding
[9,34]. Based on a series of studies using degradative
enzymes to define the presence or absence of polysaccha-
rides bound to ECM proteins, their model suggests that
perineuronal proteoglycans, such as brevican, bind to
these cell surface glycoproteins. Chase treatment removes
the terminal N-acetylgalactosamine from these glycopro-
teins, thereby releasing the lectican from its binding part-
ner on the cell surface. This may, in part, account for the
discordance in reactivity seen here between brevican and
WFA.
No direct evidence exists, to our knowledge, of WFA bind-
ing to any specific CS-containing PG, including the lecti-
cans. However, the reactivity observed with WFA and
antibodies generated against CS chains are similarly dis-
tributed in rat brain [8] (our unpublished observations),
such as in PNNs, and binding of WFA to fixed brain sec-
tions is diminished or lost after Chase treatment [35,11].
Localization of WFA and brevican reactivity in PNNs Figure 8
Localization of WFA and brevican reactivity in PNNs. Brevican immunoreactivity was found in (A and C) neuropil and 
PNNs of cortical layers II, III, deep layer IV and V. WFA immunoreactivity is predominant in (B and C) PNNs of cortical layer 
III. A higher magnification of cortex reveals PNNs that are positive for (D) brevican and (E) WFA reactivity. A confocal micro-
graph (G) of retrosplenial cortex stained with anti-brevican (green), biotinylated-WFA (red) and DAPI (blue) demonstrates a 
small subpopulation reactive for both anti-brevican and WFA (arrows). While the majority of PNNs showed only brevican 
immunoreactivity, some were identified as only WFA reactive (denoted by asterisk). Images A-C were captured at 100× mag-
nification, D-F were captured at 200× magnification and confocal image G was captured at 630×. Scale bar represents 100 μm.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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Nonetheless, there may be a host of proteins present in
ECM complexes and it is possible, in fact likely, that WFA
binds to a molecule that may be indirectly bound to CS.
In any case, no biochemical evidence is available to show
that WFA binds to large polymeric chains of repeating dis-
accharides that contain N-acetylgalactosamine.
The differential distribution between WFA and the frag-
ment of brevican may relate to their functional environ-
ment, i.e. greater abundance of intact CS-bearing PGs
chains in regions stained with WFA (more stable environ-
ment) whereas increased in proteolytic cleavage stained
the neoepitope fragment in regions that are capable of
undergoing neural plasticity. These findings are intriguing
since we observe intense immunoreactivity for the
ADAMTS-derived brevican fragment in areas thought to
be highly plastic such as the hippocampus. Therefore, the
relative abundance of cleaved proteoglycans, such as brev-
ican, in a particular region suggest a functional change in
surrounding ECM complexes which may contribute to
overall neural plasticity. However, the data presented here
only begin to uncover the intricate molecular environ-
ment around individual neurons that modulate their
function and structure.
Conclusion
A marked discordance was observed in the regional local-
ization between WFA and brevican or the proteolytically-
derived N-terminal fragment of brevican. Functionally,
this difference may correspond to regions with varied
prevalence for neural stability/plasticity.
Methods
Animals
All animal procedures described in this manuscript were
approved by the Institutional Animal Care and Use Com-
mittee (IACUC) at the University of South Florida. Adult
male C57BL/6 mice (23 g – 27 g; Harlan, Indianapolis,
IN) and adult male Sprauge-Dawley rats (250 g – 300 g;
Harlan, Indianapolis, IN) were housed under a 12 hour
light cycle with regulated temperature and humidity. Mice
were housed 3 to 4 per cage and rats were housed individ-
ually with both having free access to food and water. Brain
tissue was collected from animals between 3 and 4
months of age: For biochemical analysis n = 4 and immu-
nohistochemistry n = 6.
Western Blotting
For collection of tissue immunoblotted with antibodies
and biotin-WFA, animals were euthanatized by exposure
to excess CO2 until death and immediately decapitated.
Various brain regions were rapidly dissected and extracted
with a teflon-glass homogenizer in 5 volumes of Triton-X-
100-containing buffer (20 mM Tris-HCl at pH 7.4, 10 mM
EDTA, 1% Triton-X-100, and 1:100 protease inhibitor
cocktail [Calbiochem type III, LaJolla, CA]) for 2 minutes.
The homogenate was centrifuged in a microcentrifuge at
6800 × g for 5 minutes, and the supernatant collected and
stored at -80°C.
In some experiments, brain tissue extract was treated with
Chase prior to Western blot to determine whether WFA
recognized CS-containing proteins. Thus, 25 μl of sodium
acetate buffer (50 mM sodium acetate, 1 M Tris, 10 mM
EDTA) containing 10 mU of chondroitinase ABC (Sigma-
Aldrich, St. Louis, MO) was added to 25 μl of brain tissue
extract and incubated for 1.5 h at 37°C. To determine
whether there was protease contamination in the Chase
preparation, samples underwent Chase digestion in the
presence of a protease inhibitor cocktail. All samples were
reduced (mercaptoethanol-containing, SDS-PAGE sample
buffer), denatured for 4 minutes at 95°C, and subjected to
SDS-PAGE.
Tissue extracts were loaded (equal amounts of protein)
onto pre-cast, 1.5 mm, 4–20% gradient SDS-PAGE gels
(Novex Tris-glycine, Invitrogen, Carlsbad, CA). Separated
proteins were electrophoretically transferred to a polyvi-
nylidine difluoride membrane (PVDF, Immobilon, Milli-
pore, Billerica, MA). For brevican and EAV(M)ESE
immunoblotting, the membranes were washed with
Buffer B (10 mM phosphate buffered saline, pH 7.4 con-
taining 0.05% Tween 20) for 5 minutes, blocked for 1 h in
5% non-fat dry milk diluted in Buffer B and probed for 2
hours using primary antibodies against mouse anti-brevi-
can (1:1000, BD Transduction Labs, San Jose, CA), rabbit
anti-EAMESE (1:1000) [24] (the neoepitope sequence for
mouse brevican fragment), or rabbit anti-EAVESE (1:500)
[23,36] (the neoepitope sequence for rat brevican frag-
ment). For WFA blotting, the membranes were washed
with Buffer B for 5 minutes, blocked in 1% bovine serum
albumin diluted in Buffer B for 1 hour and probed for 2
hours using biotinylated Wisteria floribunda lectin
(1:10,000 in 1% BSA, Vector Laboratories, Burlingame,
CA) as the primary binding reagent. Primary antibodies
and biotinylated Wisteria floribunda lectin were detected
with corresponding secondary antibodies including anti-
mouse, anti-rabbit and streptavidin conjugated to horse
radish peroxidase (Chemicon, Temecula, CA), respec-
tively. Antigens were visualized using a chemilumines-
cence developing system (SuperSignal, Pierce, Rockford,
IL), and equal protein loading was verified by examining
the Commassie blue stained membrane. It should be
noted that ADAMTS-derived fragment antibodies were
raised against the species-specific neoepitopes for rat and
mouse, since they show limited cross-reactivity with one
another, ie. anti-EAVESE (rat sequence) does not effec-
tively recognize the C-terminus of the N-terminal,
ADAMTS-cleaved fragment EAMESE (murine sequence)
of mouse brevican.BMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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Isolation of Membrane Fractions
Whole rat brain was collected as descibed above and
homogenized for 1 minute with a Glas-Col (Terre Haute,
IN) motorized (low speed, 333 rpm), teflon-glass homog-
enizer in 10 volumes of 50 mM Tris-HCl, pH 7.4, 1 mM
EDTA, containing 1:100 protease inhibitor cocktail (Cal-
biochem type III, LaJolla, CA). The homogenate was cen-
trifuged at 500 × g for 5 minutes, the supernatant collected
and centrifuged at 40,000 × g to obtain soluble and insol-
uble fractions. The supernatant, "soluble" fraction, was
removed immediately, aliquoted and stored at -80°C. The
insoluble "membrane" fraction was resuspended with
buffer, centrifuged again (40,000 × g for 30 min) and
reconstituted in detergent-containing RIPA buffer (50 mM
Tris base, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton-X-100, 1% sodium deoxycholate, 1% SDS, pH =
7.4), aliquoted and stored at -80°C.
Immunohistochemistry
Rats and mice were euthanatized with excess Nembutal,
and the brains fixed via cardiac perfusion as described
[36]. Brains were cleared using phosphate buffered saline
(PBS; pH 7.4), fixed with fresh 4% paraformaldehyde in
0.1 M phosphate buffer (PB; pH 7.4), collected, post-fixed
overnight in 4% paraformaldehyde and cryoprotected
with 15% and 30% sucrose (in PBS) for 24 h each. The
individual brains were mounted on a cryostat chuck at -
20°C and sectioned at 30 μm. Sections were stored freely
floating in antifreeze solution (50 mM sodium phos-
phate, pH 7.4, 30% ethylene glycol and 30% glycerol) at -
20°C.
For Chase treated tissue, matched sections were selected,
washed three times with PBS and incubated in 500 mU of
Chase in 0.5 ml of sodium acetate buffer for 1.5 hours at
37°C. Selected sections to be used for immunohisto-
chemistry were washed in PBS for 15 minutes, blocked
and permeabilized in 10% normal goat serum, 3% 1 M
lysine and 3% Triton-X-100 for 1 h and incubated over-
night in primary antibodies anti-EAMESE (1:1000)
(Mayer et al., 2005), EAVESE (1:500) [16,36], brevican
(1:1000, N-terminal (G1); Transduction Labs, San Jose,
CA), RB18 (1:500, a generous gift from Yu Yamaguchi,
Burnham Institute, La Jolla, CA, an antibody that recog-
nizes an epitope in the G3 domain of rat brevican) and
Wisteria floribunda lectin (1:1000) at 4°C. Doubly probed
sections were washed and incubated in anti-rabbit IgG
conjugated to Alexa-Fluor 488 (Molecular Probes,
Eugene, OR) and streptavidin conjugated to Alexa-Fluor
594 (Molecular Probes, Eugene, OR) for 1 hr at room tem-
perature. The sections were washed for 15 minutes, wet
mounted on glass slides, and coverslipped with VectaSh-
ield mounting medium (Vector Labs, Burlingame, CA).
Cleavage of PGs with human recombinant ADAMTS4
PGs present in whole rat brain extracts were bound to and
eluted from a DEAE Sepharose Fast Flow cation exchange
matrix (Pharmacia, Pfizer, New York, NY) as described
[37] with modifications. All procedures were carried out
at 4°C unless otherwise stated. Briefly, rat brain tissue (1
g) was placed in 10 ml, ice cold, 4 mM HEPES pH 8.0,
0.15 mM NaCl, 0.1% Triton-X-100 containing 2 mM 1,10
phenanthroline (Sigma, St. Louis, MO) and protease
inhibitor cocktail (set III, Calbiochem, San Diego, CA).
The tissue was disrupted in a Teflon-glass homogenizer
and the extract centrifuged at 30,000 × g for 30 min. The
supernatant was removed, diluted 1:1 with 50 mM Tris-
HCl, 0.15 M NaCl, 0.1% Triton-X-100, and applied to a
DEAE column pre-equilibrated with the same buffer at a
flow rate of less than 0.5 ml per minute. The flow through
was collected, passed over the column again, and bound
proteins were eluted with 5 column volumes of consecu-
tive buffers containing 50 mM Tris-HCl pH 8.2, 0.15 M
NaCl, 0.1% Triton-X-100, then 50 mM Tris-HCl pH 8.2,
0.25 M NaCl, 6 M urea, 0.1% Triton-X-100, and fractions
containing PGs were eluted with 50 mM Tris-HCl pH 8.2,
1.0 M NaCl. PG (protein)-containing fractions were dia-
lyzed against water for 24 h in SpectraPor 6000–8000
MWCO (Millipore, Billerica, MA) membrane at 4°C, the
samples concentrated on an Eppendorf "speed-vac" and
aliquoted. Total protein was measured in the samples (1.3
μg/μl). DEAE-purified PG samples were incubated with
25 nM human recombinant ADAMTS4, (a gift of Carl
Flannery, Wyeth Pharmaceuticals, Collegeville, PA)
diluted in 10 mM Tris-HCl, 0.15 M NaCl, and 10 mM
CaCl2 for two hours at 37°C. After the incubation period,
beta-mercaptoethanol-containing, SDS-PAGE sample
buffer was added to the samples, the samples were heated
at 95°C for 4 minutes, subjected to SDS-PAGE, and elec-
trically transferred to Immobilon PVDF membrane (Mill-
ipore, Bedford, MA). Membranes were probed with
mouse anti-brevican (BD Biosciences, San Jose, CA) at
1:1000 primary antibody detected with anti-mouse conju-
gated to horse-radish peroxidase (Chemicon, Temecula,
CA), and signal detected using SuperSignal chemilumi-
nescence substrate (Pierce, Rockford, IL). The membrane
was probed a second time with anti-EAVESE (1:100) [23],
as described under the Western blot section above.
Microscopy and image acquisition
Single and multi-labeled, epifluorescent tissue sections
were viewed using a Zeiss Axioskop microscope, inter-
faced with an Axiocam and images acquired with Openlab
software. Confocal images (Fig. 8) were attained using a
Leica SP-2 confocal microscope and Leica LCS software.
Controls for each immunomarker included secondary
antibody in the absence of a primary antibody, in which
the staning in control sections was minimal to absent.
Exposure times and aperture opening were constant forBMC Neuroscience 2008, 9:14 http://www.biomedcentral.com/1471-2202/9/14
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each magnification and antibody used. Some images were
minimally and equally modified (contrast and bright-
ness) using Abobe photoshop.
List of abbrevications
PG – proteoglycan, ECM – extracellular matrix, CNS –
central nervous system, CS – chondroitin sulfate,
ADAMTS – a disintegrin and metalloproteinase with
thrombospondin motifs, WFA – Wisteria floribunda,
PNN – perineuronal net, Chase – Chondroitinase ABC,
IACUC – Institutional animal care and use committee,
PVDF – polyvinylidine difluoride, MWCo – molecular
weight cutoff.
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